Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Financial Officer

Chief Scientific Officer

Chief Legal Officer

General Counsel

EVP and COO

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of smal...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-05-02	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-04-30	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-04-30	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2024-04-30	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-04-30	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-04-30	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2024-04-30	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-02-16	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-01-30	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2024-01-30	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-01-30	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-01-30	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-01-30	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-01-30	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2023-12-20	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2023-12-19	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2023-10-31	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2023-10-31	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2023-10-31	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2023-10-30	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2023-10-30	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2023-10-30	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2023-07-31	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2023-07-31	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2023-07-31	Premium	sold	Premium	Premium	Premium	General Counsel

NRIX - Nurix Therapeutics, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for NRIX